Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-24T08:03:58.052Z Has data issue: false hasContentIssue false

95 - Nabiximols

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Sativex

Generic?

• No

Class

• Cannabinoid

Commonly Prescribed for

(FDA approved in bold)

• Spasticity and spastic pain in multiple sclerosis (MS)

• Neuropathic pain

• Advanced cancer pain

• Pain in fibromyalgia, rheumatoid arthritis

How the Drug Works

• It is composed of 1:1 mixture of 2 cannabinoids: cannabidiol (CBD) and 9-δ- tetrahydrocannabinol (THC)

• THC, a partial agonist of both cannabinoid receptors (CB1, CB2) in brain and spinal cord, reduces spasticity but causes sedation and psychotropic side effects. Its action also involves analgesia, muscle relaxation, antiinflammation, neuroprotection, and anxiolysis

• CBD reduces sedation and psychotropic side effects

How Long Until It Works

• Minutes to hours

If It Works

• Takes weeks to months for full effect. Usually within 4 weeks

If It Doesn't Work

• Treat underlying conditions. Consider addition of other agents

Best Augmenting Combos for Partial Response or Treatment-Resistance

• For spasticity, may consider use of other centrally acting muscle relaxant or botulinum toxin

• For neuropathic pain, many consider use of TCAs, SNRIs, AEDs, and opioids

Tests

• None

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Related to CB1 and CB2 agonist effect in peripheral tissues, such as sympathetic ganglia, adrenal gland, heart, lung, reproductive tissues, urinary bladder, GI tract, immune cells

Notable AEs

• Sedation, dizziness, dry mouth, nausea, headache. Administration site irritation

Life-Threatening or Dangerous AEs

• Cardiac arrhythmia, myocardial infarction

• Operational hazard (driving, heavy machinery)

• Psychosis and dependence

Weight Gain

• Not unusual

Sedation

• Common

What to Do About AEs

• Lower the dose and titrate more slowly

Best Augmenting Agents to Reduce AEs

• Most AEs cannot be reduced by an augmenting agent

DOSING AND USE

Usual Dosage Range

• 5–12 sprays per day

Dosage Forms

• Buccal spray: THC 27 mg/mL and CBD 25 mg/mL

How to Dose

• First day: 1 spray every 4 hours, maximum 4 sprays

• Titrate: spread out the doses throughout the day. Watch for adverse reactions. Titrate to a tolerated dosage with acceptable pain relief

• Maximum: 12 sprays per day

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 349 - 351
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Nabiximols
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.096
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Nabiximols
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.096
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Nabiximols
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.096
Available formats
×